Onconetix (NASDAQ:ONCO) Shares Down 4.1%

Shares of Onconetix, Inc. (NASDAQ:ONCO) were down 4.1% on Tuesday . The company traded as low as $0.15 and last traded at $0.15. Approximately 956,700 shares traded hands during trading, a decline of 86% from the average daily volume of 6,797,862 shares. The stock had previously closed at $0.16.

Onconetix Stock Performance

The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.28 and a current ratio of 0.29. The business’s 50-day simple moving average is $0.16 and its two-hundred day simple moving average is $0.16.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 1.37% of Onconetix at the end of the most recent quarter. 23.89% of the stock is currently owned by hedge funds and other institutional investors.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.